Literature DB >> 23418091

Infant baboons infected with respiratory syncytial virus develop clinical and pathological changes that parallel those of human infants.

James F Papin1, Roman F Wolf, Stanley D Kosanke, Justin D Jenkins, Sara N Moore, Michael P Anderson, Robert C Welliver.   

Abstract

Respiratory syncytial virus (RSV) infection of the lower respiratory tract is the leading cause of respiratory failure among infants in the United States of America and annually results in >300,000 deaths worldwide. Despite the importance of RSV, there is no licensed vaccine, and no specific form of therapy. This is largely due to the absence of an appropriate animal model for the evaluation of vaccines and therapeutic agents. We inoculated anesthetized infant (4 wk) baboons (Papio anubis) with a human strain of RSV intranasally or intratracheally. Baboons were monitored daily for clinical changes. Anesthetized baboons were intubated at various intervals, and bronchoalveolar lavage (BAL) was performed for viral culture and determination of leukocyte counts. Sham-infected baboons served as controls. Necropsies were performed on infected baboons on days 1, 3, 5, 8, or 13 after inoculation, with pathological analysis and immunohistochemical staining of lung tissues to detect RSV antigen. Infected baboons developed tachypnea and reduced oxygenation peaking from 4 to 8 days after infection and persisting for ≥14 days. Virus was recoverable in BAL fluid up to 8 days following infection. Necropsy revealed intense interstitial pneumonia, sloughing of the bronchiolar epithelium, and obstruction of the bronchiolar lumen with inflammatory cells and sloughed epithelial cells. RSV antigen was identified in bronchiolar and alveolar epithelium. We conclude that RSV-infected infant baboons develop clinical and pathological changes that parallel those observed in human infants with RSV infection. The infant baboon represents a much-needed model for studying the pathogenesis of RSV infection and evaluating antivirals and vaccines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23418091      PMCID: PMC3625990          DOI: 10.1152/ajplung.00173.2012

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  36 in total

1.  Experimental respiratory syncytial virus pneumonia in cebus monkeys.

Authors:  L S Richardson; R B Belshe; D L Sly; W T London; D A Prevar; E Camargo; R M Chanock
Journal:  J Med Virol       Date:  1978       Impact factor: 2.327

2.  Experimental respiratory syncytial virus infection of four species of primates.

Authors:  R B Belshe; L S Richardson; W T London; D L Sly; J H Lorfeld; E Camargo; D A Prevar; R M Chanock
Journal:  J Med Virol       Date:  1977       Impact factor: 2.327

3.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  Respiratory syncytial virus infection in owl monkeys: viral shedding, immunological response, and associated illness caused by wild-type virus and two temperature-sensitive mutants.

Authors:  G A Prince; S C Suffin; D A Prevar; E Camargo; D L Sly; W T London; R M Chanock
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

5.  Respiratory syncytial virus is associated with an inflammatory response in lungs and architectural remodeling of lung-draining lymph nodes of newborn lambs.

Authors:  Fatoumata B Sow; Jack M Gallup; Alicia Olivier; Subramaniam Krishnan; Andriani C Patera; JoAnn Suzich; Mark R Ackermann
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-08       Impact factor: 5.464

6.  Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999.

Authors:  Shelah Leader; Kimmie Kohlhase
Journal:  Pediatr Infect Dis J       Date:  2002-07       Impact factor: 2.129

7.  Quantitative estimates of sequence divergence for comparative analyses of mammalian genomes.

Authors:  Gregory M Cooper; Michael Brudno; Eric D Green; Serafim Batzoglou; Arend Sidow
Journal:  Genome Res       Date:  2003-05       Impact factor: 9.043

8.  Decreased interferon-gamma response in respiratory syncytial virus compared to other respiratory viral infections in infants.

Authors:  J H Aberle; S W Aberle; W Rebhandl; E Pracher; M Kundi; T Popow-Kraupp
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

9.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.

Authors:  B S Graham; L A Bunton; P F Wright; D T Karzon
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

10.  The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class-specific responses.

Authors:  R C Welliver; T N Kaul; T I Putnam; M Sun; K Riddlesberger; P L Ogra
Journal:  J Pediatr       Date:  1980-05       Impact factor: 4.406

View more
  21 in total

Review 1.  A review of metabolomics approaches and their application in identifying causal pathways of childhood asthma.

Authors:  Kedir N Turi; Lindsey Romick-Rosendale; Kelli K Ryckman; Tina V Hartert
Journal:  J Allergy Clin Immunol       Date:  2017-05-04       Impact factor: 10.793

2.  RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction.

Authors:  Rachael M Liesman; Ursula J Buchholz; Cindy L Luongo; Lijuan Yang; Alan D Proia; John P DeVincenzo; Peter L Collins; Raymond J Pickles
Journal:  J Clin Invest       Date:  2014-04-08       Impact factor: 14.808

3.  Using urine metabolomics to understand the pathogenesis of infant respiratory syncytial virus (RSV) infection and its role in childhood wheezing.

Authors:  Kedir N Turi; Lindsey Romick-Rosendale; Tebeb Gebretsadik; Miki Watanabe; Steven Brunwasser; Larry J Anderson; Martin L Moore; Emma K Larkin; Ray Stokes Peebles; Tina V Hartert
Journal:  Metabolomics       Date:  2018-10-01       Impact factor: 4.290

4.  Comparative Analysis of Cellular Immune Responses in Conventional and SPF Olive Baboons (Papio anubis).

Authors:  Elizabeth R Magden; Bharti P Nehete; Sriram Chitta; Lawrence E Williams; Joe H Simmons; Christian R Abee; Pramod N Nehete
Journal:  Comp Med       Date:  2020-02-03       Impact factor: 0.982

Review 5.  Animal models of bronchopulmonary dysplasia. The preterm baboon models.

Authors:  Bradley A Yoder; Jacqueline J Coalson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-03       Impact factor: 5.464

6.  Oxysophocarpine inhibits lung injury induced by respiratory syncytial virus.

Authors:  Jie Gao; Ying Li; Qiwei Wang; Xiaojian Ma; Yan Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

Review 7.  Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.

Authors:  Swapnil Subhash Bawage; Pooja Munnilal Tiwari; Shreekumar Pillai; Vida Dennis; Shree Ram Singh
Journal:  Adv Virol       Date:  2013-12-09

8.  The effect of TIP on pneumovirus-induced pulmonary edema in mice.

Authors:  Elske van den Berg; Reinout A Bem; Albert P Bos; Rene Lutter; Job B M van Woensel
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

9.  RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function.

Authors:  Jane Tian; Kelly Huang; Subramaniam Krishnan; Catherine Svabek; Daniel C Rowe; Yambasu Brewah; Miguel Sanjuan; Andriani C Patera; Roland Kolbeck; Ronald Herbst; Gary P Sims
Journal:  J Gen Virol       Date:  2013-04-04       Impact factor: 3.891

10.  Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation.

Authors:  B David Persson; Aron B Jaffe; Rachel Fearns; Henry Danahay
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.